Analysis of mechanisms for immunosuppression through ILT7/NKp44/BDCA2 ligands expressed on cancer cells
Project/Area Number |
22501025
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Tumor immunology
|
Research Institution | Keio University |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
KAWAKAMI Yutaka 慶應義塾大学, 医学部, 教授 (50161287)
|
Project Period (FY) |
2010 – 2012
|
Project Status |
Completed (Fiscal Year 2012)
|
Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2012: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2011: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2010: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
Keywords | 免疫抑制 / プラズマ細胞様樹状細胞 / ILT7 / NKp44 / BDCA2 |
Research Abstract |
To clarify the mechanisms of immunosuppression through ILT7/NKp44/BDCA2 ligands expressed on cancer cells, we tried to identify these ligands molecularly and successfully cloned the NKp44L. Furthermore, we showed a signal pathway, which could control the
|
Report
(4 results)
Research Products
(30 results)
-
-
-
-
[Journal Article] Cancer-testis antigen BORIS is a novel prognostic marker for patients with esophageal cancer.2012
Author(s)
Okabayashi K, Fujita T, Miyazaki J, Okada T, Iwata T, Hirao N, Noji S, Tsukamoto N, Goshima N, Hasegawa H, Takeuchi H, Ueda M, Kitagawa Y, Kawakami Y.
-
Journal Title
Cancer Sci.
Volume: 103
Pages: 1617-1624
Related Report
Peer Reviewed
-
-
-
[Journal Article] Cancer-testis antigen BORIS is a novel prognostic marker for patients with esophageal cancer.2012
Author(s)
Okabayashi K, Fujita T, Miyazaki J, Okada T, Iwata T, Hirao N, Noji S, Tsukamoto N, Goshima N, Hasegawa H, Takeuchi H, Ueda M, Kitagawa Y, Kawakami Y.
-
Journal Title
Cancer Sci
Volume: 103(9)
Issue: 9
Pages: 1617-24
DOI
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-